CIK 0001858848
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Tenaya Therapeutics, Inc.
Sign in to watch- Ticker
- TNYA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813789973
- Phone
- +1 415-865-2066
- Business address
- 171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-24 | Tingley Whittemore Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +69,982 | 69,982 | ||
| 2025-01-24 | Tingley Whittemore Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −141,000 | 0 | ||
| 2025-01-24 | Tingley Whittemore Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +141,000 | 141,000 | ||
| 2025-01-24 | Tingley Whittemore Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −205,000 | 0 | ||
| 2025-01-24 | Tingley Whittemore Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +205,000 | 205,000 | ||
| 2025-01-24 | Tingley Whittemore Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −215,000 | 0 | ||
| 2025-01-24 | Tingley Whittemore Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +215,000 | 215,000 | ||
| 2024-11-18 | Saito Chihiro SVP, Accounting and Fin. Ops. | Sale | −2,258 | $2.12 | $5K | 60,983 |
| 2024-10-18 | Walsh Jeffrey T. Director | Grant or award · Stock Option (Right to buy) | +34,000 | 34,000 | ||
| 2024-10-18 | Williams R Sanders Director | Grant or award · Stock Option (Right to buy) | +34,000 | 34,000 | ||
| 2024-10-18 | Stehman-Breen Catherine Director | Grant or award · Stock Option (Right to buy) | +34,000 | 34,000 | ||
| 2024-10-18 | Srivastava Deepak Director | Grant or award · Stock Option (Right to buy) | +34,000 | 34,000 | ||
| 2024-10-18 | Parschauer Karah Herdman Director | Grant or award · Stock Option (Right to buy) | +34,000 | 34,000 | ||
| 2024-10-18 | Lee June Director | Grant or award · Stock Option (Right to buy) | +34,000 | 34,000 | ||
| 2024-10-18 | GOEDDEL DAVID V Director | Grant or award · Stock Option (Right to buy) | +34,000 | 34,000 | ||
| 2024-10-18 | Burroughs Amy L. Director | Grant or award · Stock Option (Right to buy) | +34,000 | 34,000 | ||
| 2024-08-16 | Saito Chihiro SVP, Accounting and Fin. Ops. | Sale | −902 | $2.89 | $3K | 64,702 |
| 2024-08-16 | Saito Chihiro SVP, Accounting and Fin. Ops. | Sale | −654 | $2.89 | $2K | 64,048 |
| 2024-08-16 | Saito Chihiro SVP, Accounting and Fin. Ops. | Sale | −807 | $2.89 | $2K | 63,241 |
| 2024-08-16 | Tingley Whittemore Chief Medical Officer | Sale | −5,803 | $2.89 | $17K | 108,731 |
Page 6 of 12 · 228 trades